For IL-33-induced airway inflammation, mice were anesthetized using isoflurane and treated three times intranasally or intratracheally every other day with 0.5 µg IL-33 (BioLegend, USA) or PBS (GIBCO Life Technologies, USA) as described previously (17 (link)). Mice were sacrificed at the indicated time points after the final IL-33 administration.
For acute HDM-induced allergic airway inflammation, mice were anesthetized using isoflurane and sensitized by intranasal or intratracheal injection with 1 or 10 µg HDM extract (Greer, SC, USA) or PBS. After 7 days, animals were challenged daily on days 0–4 with 10 µg HDM intranasally or intratracheally and sacrificed at the indicated time points after the final treatment as described previously (46 (link)). For chronic HDM-induced allergic airway inflammation, mice were anesthetized using isoflurane and treated intranasally three times weekly for 5 weeks with 25 µg HDM or PBS and sacrificed at the indicated time points after the final treatment [adapted from Ref. (47 (link))].
For acute HDM-induced allergic airway inflammation, mice were anesthetized using isoflurane and sensitized by intranasal or intratracheal injection with 1 or 10 µg HDM extract (Greer, SC, USA) or PBS. After 7 days, animals were challenged daily on days 0–4 with 10 µg HDM intranasally or intratracheally and sacrificed at the indicated time points after the final treatment as described previously (46 (link)). For chronic HDM-induced allergic airway inflammation, mice were anesthetized using isoflurane and treated intranasally three times weekly for 5 weeks with 25 µg HDM or PBS and sacrificed at the indicated time points after the final treatment [adapted from Ref. (47 (link))].
Free full text: Click here
